Hong Kong
· Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 64.16 billion. The enterprise value is 167.35 billion.
| Market Cap | 64.16B |
| Enterprise Value | 167.35B |
Important Dates
The next estimated earnings date is Thursday, March 26, 2026.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has decreased by -0.36% in one year.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | -0.36% |
| Shares Change (QoQ) | -82.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 28.11% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 8.29 and the forward PE ratio is 7.52. Sinopharm Group's PEG ratio is 1.65.
| PE Ratio | 8.29 |
| Forward PE | 7.52 |
| PS Ratio | 0.10 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | 3.10 |
| P/OCF Ratio | 2.91 |
| PEG Ratio | 1.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.60, with an EV/FCF ratio of 8.08.
| EV / Earnings | 21.63 |
| EV / Sales | 0.27 |
| EV / EBITDA | 6.60 |
| EV / EBIT | 8.23 |
| EV / FCF | 8.08 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.63.
| Current Ratio | 1.35 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 3.79 |
| Debt / FCF | 4.39 |
| Interest Coverage | 6.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 12.24% |
| Revenue Per Employee | 5.79M |
| Profits Per Employee | 71,481 |
| Employee Count | 108,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sinopharm Group has paid 4.27 billion in taxes.
| Income Tax | 4.27B |
| Effective Tax Rate | 27.83% |
Stock Price Statistics
The stock price has decreased by -1.86% in the last 52 weeks. The beta is 0.59, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -1.86% |
| 50-Day Moving Average | 19.59 |
| 200-Day Moving Average | 19.01 |
| Relative Strength Index (RSI) | 57.14 |
| Average Volume (20 Days) | 5,249,603 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 626.85 billion and earned 7.74 billion in profits. Earnings per share was 2.48.
| Revenue | 626.85B |
| Gross Profit | 46.38B |
| Operating Income | 19.03B |
| Pretax Income | 15.35B |
| Net Income | 7.74B |
| EBITDA | 21.43B |
| EBIT | 19.03B |
| Earnings Per Share (EPS) | 2.48 |
Balance Sheet
The company has 42.38 billion in cash and 91.01 billion in debt, giving a net cash position of -48.63 billion or -15.58 per share.
| Cash & Cash Equivalents | 42.38B |
| Total Debt | 91.01B |
| Net Cash | -48.63B |
| Net Cash Per Share | -15.58 |
| Equity (Book Value) | 144.45B |
| Book Value Per Share | 28.81 |
| Working Capital | 104.87B |
Cash Flow
In the last 12 months, operating cash flow was 22.06 billion and capital expenditures -1.34 billion, giving a free cash flow of 20.72 billion.
| Operating Cash Flow | 22.06B |
| Capital Expenditures | -1.34B |
| Free Cash Flow | 20.72B |
| FCF Per Share | 6.64 |
Margins
Gross margin is 7.40%, with operating and profit margins of 3.04% and 1.23%.
| Gross Margin | 7.40% |
| Operating Margin | 3.04% |
| Pretax Margin | 2.45% |
| Profit Margin | 1.23% |
| EBITDA Margin | 3.42% |
| EBIT Margin | 3.04% |
| FCF Margin | 3.31% |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 3.64%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 3.64% |
| Dividend Growth (YoY) | -22.70% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 10.73% |
| Buyback Yield | 0.36% |
| Shareholder Yield | 4.01% |
| Earnings Yield | 12.06% |
| FCF Yield | 32.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.1 |
| Piotroski F-Score | 3 |